COVID Patient Infusion for Monoclonal antibody therapy has been approved under an FDA Emergency Use Authorization (EUA) for the treatment of COVID-19 in non-hospitalized adults with mild to moderate symptoms and who are at high risk of needing hospitalization for severe COVID-19. High-risk patients include those who meet any of the following: age 65 or older; 18 years of age and older with a body mass index (BMI) of at least 35; or 18 years of age and older with a high-risk medical condition such as hypertension, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, immunosuppressive disease, etc. The greatest benefit to the treatment is within five days of COVID-19 symptom onset. If it has been more than 10 days since symptoms began patients are ineligible for the treatment.
Appointments for infusion are available at McLeod Regional Medical Center, McLeod Health Clarendon, and McLeod Health Seacoast. Healthcare providers may use the referral form below to begin the process of scheduling patients for treatment.
If you are a healthcare provider:
If you are a patient and do not have a primary care provider:
COVID Infusion Therapy uses a neutralizing antibody drug. It contains man-made antibodies similar to the antibodies of people who have recovered from COVID. It does not contain any COVID-19 virus or parts and does not come from another person who has had COVID. Click here for FAQs.